Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis
Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis
复制标题
DOI：
10.1097/moh.0b013e3283386660
复制
发表时间：
2010-05-01
影响因子：
3.2
通讯作者：
Ferrara, Napoleone
中科院分区：
文献类型：
--
作者：
Ferrara, Napoleone
综述目的靶向血管内皮生长因子（VEGF）通路在癌症和眼内新生血管疾病的治疗中具有重要影响。与其他疗法类似，癌症患者可能会对抗VEGF药物产生固有/获得性耐药性，导致疾病复发。本文综述了髓系细胞在难治性或/和获得性耐药等therapy.Recent findingsVarious髓系细胞类型，包括肿瘤相关巨噬细胞，Tie 2-表达单核细胞和中性粒细胞的作用的最新研究结果，已牵连在肿瘤血管生成。参与这些细胞的动员和/或促血管生成作用的几种细胞因子代表了治疗靶点。CD 11b（+）Gr 1（+）髓样细胞已显示使肿瘤对VEGF抗体的血管生成阻断难治。这种效果是由分泌的蛋白Bv 8，这是上调的粒细胞集落刺激factor.SummaryProgress在解开依赖于各种骨髓细胞类型的促血管生成机制，扩大了我们对肿瘤血管生成的理解，并产生了一些潜在的治疗目标。
Purpose of reviewTargeting the vascular endothelial growth factor (VEGF) pathway has had a significant impact in the therapy of cancer and intraocular neovascular disorders. Similar to other therapies, inherent/acquired resistance to anti-VEGF drugs may occur in cancer patients, leading to disease recurrence. This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies.Recent findingsVarious myeloid cell types, including tumor-associated macrophages, Tie2-expressing monocytes and neutrophils, have been implicated in tumor angiogenesis. Several cytokines involved in the mobilization and/or proangiogenic effects of these cells represent therapeutic targets. CD11b(+)Gr1(+) myeloid cells have been shown to render tumors refractory to angiogenic blockade by VEGF antibodies. This effect was mediated by the secreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor.SummaryProgress in unraveling proangiogenic mechanisms dependent on various myeloid cell types has expanded our understanding of tumor angiogenesis and has generated a number of potential therapeutic targets.